[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Apollo Therapeutics Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":130},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,74,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100637567","phase-2-a-phase-2b-study-of-the-effects-of-camoteskimab-in-adults-with-moderate-to-severe-atopic-dermatitis-100637567",false,"NCT07599813","A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n1. Age 18-65 inclusive, at the time of signing the informed consent.\n2. Chronic AD for at least 1 year based on clinically confirmed diagnosis of active AD, according to Hanfin and Rajka criteria.\n3. Participants with moderate-to-severe AD defined by:\n\n   1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Screening and Baseline.\n   2. AD involvement of ≥ 10% body surface area (BSA) at Screening and Baseline.\n   3. EASI score of ≥ 16 at Screening and at Baseline.\n   4. Peak pruritus numerical rating scale (PP-NRS) ≥ 4 at Baseline. Note: The PP-NRS will be calculated from the 7 consecutive days immediately preceding Baseline. A minimum of 4 daily scores out of the 7 days is needed.\n4. Participants who are candidates for systemic therapy, defined as history of inadequate response to topical AD treatments applied for at least 28 days, or for the maximum duration recommended by the product prescribing information, or for treatment with topical AD treatments is medically inadvisable due to important side effects or safety risks.\n5. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n6. Participant provides signed informed consent\n\nExclusion Criteria:\n\n1. History or other evidence of severe illness or any other conditions such as psychiatric illness, severe depression or previous history of suicidal attempt in past 10 years that would render the participant, in the opinion of the Investigator, unsuitable for the study.\n2. Active, chronic or acute infection requiring systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the Baseline.\n3. Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments based on the Investigator's judgement.\n4. Participant has history of significant flares of AD within 4 weeks prior to screening, in the opinion of the investigator.\n5. Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma) based on investigator judgement.\n6. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QTc interval changes.\n7. Participant has severe and uncontrolled seasonal or allergic rhinitis, severe and uncontrolled asthma or any other severe and uncontrolled atopic disease as judged by the Investigator.\n8. Treatment of AD with medicated moisturizers available only by prescription within 2 weeks prior to the Baseline visit.\n9. Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIV Ab) test.\n10. Active hepatitis B virus (HBV): hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+) confirmed by HBV PCR positive (+).\n11. Active hepatitis C virus (HCV): If hepatitis C antibody positive (+), confirmed by HCV RNA test. Note: a participant with documented proof of cure from HCV may be enrolled.\n12. Evidence of active or latent tuberculosis.\n13. Receipt of live or attenuated live vaccine within 6 weeks prior to screening.\n14. Participant had a major surgery within 8 weeks prior to Baseline or has a major surgery planned during the study.\n15. Participant is known to have immune deficiency or is immunocompromised\n16. Diagnosed with a malignancy within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue biopsy, as applicable) with the exception of:\n\n    * Completely resected basal cell or squamous cell carcinoma of the skin.\n    * Carcinoma in situ of the cervix.\n17. Has had previous exposure to anti-IL-18 therapy.\n18. Known allergy\u002Fsensitivity to any component of IMP.\n19. History of use of any of these medications as follows:\n\n    1. Dupilumab, tralokinumab, lebrikizumab, nemolizumab within 8 weeks prior to Baseline.\n    2. Systemic JAKi within 4 weeks prior to Baseline.\n    3. Any topical medicated treatment that could affect AD within 2 weeks prior to Baseline, including, but not limited to, topical corticosteroids, topical phosphodiesterase (PDE4) inhibitors, topical calcineurin inhibitors, topical JAKi, tars, antimicrobials, medical devices, and bleach baths.\n    4. Systemic therapies (other than biologics) that could affect AD not noted above, within 4 weeks prior to Baseline, including but not limited to, retinoids, calcineurin inhibitors, methotrexate, hydroxycarbamide (hydroxyurea), azathioprine, oral\u002Finjectable corticosteroids. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.\n    5. Treatment with any investigational biologic agent or biologic agent approved after publication of this protocol, within 12 weeks (or 5 half-lives, whichever is greater) of screening.\n    6. Treatment with any investigational nonbiologic agent, or any investigational device or procedure, within 4 weeks (or 5 half-lives, whichever is greater) of screening.\n    7. UV-B phototherapy (including tanning beds) or excimer laser use within 4 weeks prior to Baseline or during the study.\n    8. PUVA treatment within 4 weeks prior to Baseline\n    9. Sedating antihistamines, including but not limited to doxepin, hydroxyzine or diphenhydramine within 1 week prior to Baseline\n    10. Topical products containing urea within 1 week prior to Baseline\n    11. Systemic antibiotics within 2 weeks or topical antibiotics within 1 week prior to Baseline\n    12. Intravenous immunoglobulin (IVIg) therapy within 12 weeks prior to Baseline.\n20. Female participant who is pregnant or breastfeeding or trying to conceive.\n21. Participant considered unlikely to adhere to treatment and\u002For follow the protocol in the opinion of the Investigator.","ALL","18 Years","65 Years",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.",[27,28,29,30,31,32,33,34],"Atopic Dermatitis","Atopic","Dermatitis","Dermatitis, Atopic","Dermatologic Disease","Eczema","Eczema Atopic Dermatitis","Eczema, Atopic","RECRUITING","2026-05-29",{"date":38,"type":39},"2026-06-02","ACTUAL",{"date":41,"type":39},"2026-05-28",{"date":43,"type":21},"2028-04-30",{"name":45,"class":46},"Apollo Therapeutics Ltd","INDUSTRY",85,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100544732","phase-1-a-study-to-investigate-apl-4098-alone-and-in-combination-in-adults-with-aml-or-mds-100544732","NCT06372717","A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS","A Phase 1 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and in Combination With Azacitidine and in Combination With Azacitidine Plus Venetoclax in Adults With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome\u002FAML (MDS\u002FAML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB)","Inclusion Criteria:\n\n* 18 years or older\n* Confirmed diagnosis of relapsed refractory acute myeloid leukemia (R\u002FR AML), myelodysplastic syndrome (MDS)\u002F AML, or MDS-excess blasts (MDS-EB) with the following characteristics: - R\u002FR AML (primary or secondary, including treatment-related), participant is intolerant to, or considered ineligible for available therapies known to provide clinical benefit.\n* WBC count ≤ 25,000\u002Fmicroliter\n* ECOG Performance Status of ≤ 2\n* Weight ≥ 40kg\n* Female participants of childbearing potential must have negative serum pregnancy test at screening; must not plan to become pregnant or have ova harvested or breastfeed while on study; must be willing to use specific contraception or avoid intercourse\n* Male participants must be willing to use specific contraception and not plan to impregnant a female partner or donate sperm while on study\n* Participant must be willing and able to provide written informed consent and to comply with the requirements of the trial\n\nExclusion Criteria:\n\n* Certain prior therapies such as: received an allogeneic stem cell transplant within 6 months of screening, received an autologous stem cell transplant within 3 months of screening, received any anti-cancer treatments within 2 weeks of Cycle 1 Day 1, prior radiation therapy within 4 weeks of screening\n* Certain medical conditions such as: other malignancies, myocardial infarction within 6 months of screening, symptomatic congestive heart failure, uncontrolled active infection, history of arterial thrombosis within 6 months of screening\n* Diagnostic assessments: Left ventricular ejection fraction \\\u003C 45%, Fridericia's corrected QT interval \\> 470msec, Aspartate aminotransferase and\u002For alanine aminotransferase \\> 3 x upper limit of normal (ULN), total bilirubin \\> 1.5 x ULN, calculated or measured creatinine clearance \\\u003C 45 mL\u002Fminute (multiply by 0.85 if female)\n* Infectious disease: HIV positive, active hepatitis B and\u002For C",{"count":56,"type":21},100,[58],"PHASE1","This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with azacitidine plus venetoclax for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)\u002FAML and MDS-excess blasts (EB).",[61,62,63,64,65],"Acute Myeloid Leukemia Refractory","Myelodysplastic Syndrome Acute Myeloid Leukemia","Myelodysplastic Syndrome With Excess Blasts","Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia (AML)",{"date":67,"type":39},"2026-06-01",{"date":69,"type":39},"2024-06-04",{"date":71,"type":21},"2027-05-01",{"name":45,"class":46},9,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100581149","phase-2-a-trial-of-apl-9796-in-adults-with-pulmonary-hypertension-100581149","NCT06846554","A Trial of \"APL-9796'' in Adults With Pulmonary Hypertension","A Phase 2, Multicentre, Open-Label Trial to Evaluate APL-9796 in Adult Participants With Pulmonary Hypertension (ViTAL-PH)","ViTAL-PH","Inclusion Criteria:\n\n1. Participant must be 18 to 80 years of age inclusive\n2. Participants who are diagnosed with pulmonary hypertension via right heart catheterisation (RHC), documented at any time prior to Screening.\n3. WHO Functional Class II or III\n4. Participant has the CardioMEMS PA Sensor implanted.\n\nExclusion Criteria:\n\n1. Hospital admission related to PH within 3 months prior to Screening.\n2. Major surgical procedure within 3 months prior to Screening, unless participant is assessed as completely recovered by the Investigator\n3. Diagnosis of PH due to human immunodeficiency virus, portal hypertension, schistosomiasis, or uncorrected congenital heart disease\n4. History of left-sided heart disease and\u002For clinically significant cardiac disease\n5. History of uncontrolled systemic hypertension\n6. eGFR ≤30 ml\u002Fmin\u002F1.73m2\n7. Life expectancy of \\\u003C 12 months, as assessed by the Investigator\n8. Diagnosed with a malignancy within 5 years of enrolment\n9. Contraindications to protocol-required imaging (MRI), diagnostic, or sampling methods","80 Years",{"count":84,"type":21},48,[24],"The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796.\n\nThe trial will be conducted in two parts:\n\n* Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH).\n* Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).",[88],"Pulmonary Arterial Hypertension",[90,91,92],"Pulmonary Hypertension","WHO group 3","WHO group 1 PH","2026-05-06",{"date":95,"type":39},"2026-05-11",{"date":97,"type":39},"2025-04-09",{"date":99,"type":21},"2027-09-30",{"name":45,"class":46},6,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":73},"100546807","phase-1-a-study-to-investigate-apl-5125-in-adults-with-advanced-solid-tumors-100546807","NCT06399757","A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","A Phase 1\u002F2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* 18 years or older\n* Phase 1: Histologically confirmed locally advanced, inoperable, or metastatic tumor; Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma.\n* For Phase 1 sub-studies: Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer\n* Phase 2: Colorectal carcinoma\n* No available standard of care therapy or participant is ineligible for standard of care therapy, except in CRC tumor type in which participant must have previously received all the following therapeutic agents:\n\n  * fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy\n  * an anti-VEGF therapy\n  * if wt-RAS (wt-KRAS and wt-NRAS), an anti-EGFR therapy\n* Eastern Cooperative Oncology Group (ECOG) ≤1\n* Body Weight ≥40 kg.\n* Female participants of childbearing potential must have negative serum pregnancy test at screening; must not plan to become pregnant or have ova harvested or breastfeed while on study; must be willing to use specific contraception or avoid intercourse\n* Male participants must be willing to use specific contraception and not plan to impregnate a female partner or donate sperm while on study\n* Participant must be willing and able to provide written informed consent and to comply with the requirements of the trial\n\nExclusion Criteria:\n\n* Certain medical conditions such as: active brain metastases, carcinomatous meningitis, unstable angina pectoris, myocardial infarction or clinically significant ventricular arrhythmias, symptomatic congestive heart failure, uncontrolled active infection, history of significant hemorrhage within 4 weeks of the first dose date, intestinal disease or major gastric surgery, arterial thrombosis within 6 months of screening\n* Certain prior therapies such as: anti-cancer treatment within 2 weeks of Cycle 1 Day 1, prior radiotherapy within 14 days before screening, active anti-coagulation therapy, over the counter or prescription medications within 14 days or 5 half-lives prior to cycle 1 day 1, herbal medicines and supplements within 14 days\n* Major surgery within 1 month of screening\n* Hemoglobin \\\u003C 9.0 g\u002FdL\n* Absolute neutrophil count \\\u003C 1.5 x 10\\^9\u002FL\n* Platelet count \\\u003C 100 x 10\\^9\u002FL\n* Hepatic function:\n\n  1. Aspartate aminotransferase and\u002For alanine aminotransferase (ALT) \\>3 × upper limit of normal (ULN) (\\>5 x ULN for subjects with liver metastases)\n  2. Total bilirubin \\>1.5 × ULN (except participants with Gilbert's syndrome).\n  3. Albumin \\\u003C 3 g\u002FdL\n* Calculated or measured creatinine clearance of \\\u003C60 mL\u002Fminute calculated using the formula of Cockcroft and Gault (\\[140 - Age\\] × Mass \\[kg\\] \u002F \\[72 × serum creatinine mg\u002FdL\\]). Multiply result by 0.85 if female.\n* Fridericia's corrected QT interval (QTcF) \\>470 msec or a family history of Long QT Syndrome.\n* Cardiac function: Echocardiogram (or MUGA) showing Left Ventricular Ejection Fraction (LVEF) \\\u003C45% at rest\n* Infectious diseases: positive for HIV (unless controlled with active retroviral therapy), hepatitis B and hepatitis C",{"count":56,"type":21},[58,24],"This is an open-label, Phase 1\u002F2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).",[113,114,115,116,117,118,119,120,121],"Colorectal Cancer","Cholangiocarcinoma","Appendiceal Adenocarcinoma","Pancreatic Adenocarcinoma","Gastric Adenocarcinoma","Endometrial Adenocarcinoma","Triple Negative Breast Cancer","Ovarian Cancer","Prostate Cancer","2026-01-05",{"date":124,"type":39},"2026-01-07",{"date":126,"type":39},"2024-06-18",{"date":128,"type":21},"2027-05",{"name":45,"class":46},""]